Larazotide acetateIntestinal barrier peptide in clinical research
Larazotide has been studied as an addition to a gluten-free diet in coeliac disease. It targets intestinal barrier regulation rather than digesting gluten or replacing dietary treatment.
What is Larazotide acetate?
Larazotide acetate is a short peptide investigated as an additional treatment for persistent symptoms in coeliac disease while continuing a gluten-free diet.
How it works
It is intended to influence intestinal tight-junction regulation. A proposed barrier effect must be distinguished from demonstrated symptom or mucosal benefit.
Effects studied
Persistent coeliac symptoms
A randomised study enrolled 342 people with persistent symptoms despite a gluten-free diet. 1
Evidence: Clinical symptom research; it does not establish that gluten exposure becomes safe or that intestinal injury is healed.
What does the evidence show?
Controlled coeliac-disease symptom study; broader programme not fully reviewed
The barrier is part of the question
Cells lining the intestine are joined by structures called tight junctions. Larazotide is a short peptide investigated for its effects on regulation of this barrier. The rationale is that changing passage across the lining might influence the response to gluten in coeliac disease.
The study kept the diet in place
A randomised trial enrolled 342 adults with ongoing symptoms despite a gluten-free diet. Participants continued that diet while the medicine or placebo was tested. The study asked whether an additional treatment could help persistent symptoms; it did not test a return to unrestricted gluten intake. 1
Symptoms and intestinal injury are different
Feeling better does not necessarily mean that intestinal damage has resolved. Barrier measurements, symptoms and coeliac immune markers describe different aspects of the condition. Reporting each separately makes clear what has changed; the broad claim of “healing a leaky gut” obscures those differences.
What remains to be established
The archived references describe uncertainty in later-stage development, so an early positive finding should not be treated as a completed clinical programme. Persistent symptoms can also have more than one cause. Further work needs to establish sustained benefit and safety as an add-on treatment for diagnosed coeliac disease. It would not justify a general supplement claim for digestive complaints.
Safety & status
Its investigational role does not replace gluten avoidance or assessment of continuing symptoms. The retained trial alone is not a complete long-term safety evaluation.
Country and product status
Country-specific product availability and authorisation require a separate current check.
Frequently asked questions
Would it allow someone with coeliac disease to eat gluten?
The trial studied it alongside a gluten-free diet and does not establish that deliberate gluten exposure is safe. 1
Does symptom improvement mean the intestine has healed?
No. Symptoms and mucosal injury are distinct outcomes and need separate assessment.
Sources
This entry was rewritten from our research archive. References below are reading leads unless a completed check is explicitly noted; a full independent evidence and regulatory review is still pending.
- Leffler et al. · Larazotide in persistent coeliac symptoms Primary trial abstract · Primary trial abstract checked 27 October 2026; full paper and supplementary data not independently reviewed.
- Larazotide acetate · retained archive reference Archive research lead · Retained archive reference; not independently checked for this draft
- Larazotide acetate · retained archive reference Archive research lead · Retained archive reference; not independently checked for this draft
Research provenance
This name was discovered in the Superpower peptide index, archived 26 October 2026. Its ratings and reviewer attribution have not been adopted as our own. The archive informed this original editorial draft; independent source review is still pending.